You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Residual invasive breast cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Trial (SHR-A1811,

Not yet recruiting
  • HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
  • (no location specified)
Nov 7, 2023

Residual Disease in Breast Cancer Remission After Primary

Recruiting
  • Breast Cancer
  • minimally invasive preoperative image-guided vacuum-assisted biopsy
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori
Jul 10, 2023

Locally Advanced Breast Cancer Trial in Shanghai (pyrotinib)

Recruiting
  • Locally Advanced Breast Cancer
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Aug 11, 2022

Triple Negative Breast Cancer Trial in United States (Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine)

Recruiting
  • Triple Negative Breast Cancer
  • Sacituzumab govitecan-hziy (SG)
  • +2 more
  • Glendale, Arizona
  • +7 more
Jan 26, 2023

ResiduAl Cancer With Liquid Biopsy Evaluation

Recruiting
  • Bladder Carcinoma
  • +14 more
  • Guardant Reveal
  • Redwood City, California
    Redwood City
Sep 7, 2022

Bilateral Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Oak Lawn, Houston (Best Practice, Ixabepilone)

Active, not recruiting
  • Bilateral Breast Carcinoma
  • +2 more
  • Oak Lawn, Illinois
  • +2 more
Mar 10, 2022

Trastuzumab Emtansine in HER2-positive Breast Cancer Residual

Recruiting
  • Breast Cancer
  • Trastuzumab emtansine
  • Prato, Firenze, Italy
  • +27 more
Mar 2, 2023

Triple Negative Breast Tumors Trial (Pembrolizumab injection, Capecitabine tablets, Local radiotherapy)

Not yet recruiting
  • Triple Negative Breast Neoplasms
  • Pembrolizumab injection
  • +2 more
  • (no location specified)
Jul 25, 2023

Breast Cancer, HER2-positive Breast Cancer Trial in Toronto (Neratinib)

Not yet recruiting
  • Breast Cancer
  • HER2-positive Breast Cancer
  • Toronto, Ontario, Canada
    University Health Network: Princess Margaret Cancer Centre
Oct 31, 2022

Breast Cancer Stage I Trial (Microwave ablation)

Not yet recruiting
  • Breast Cancer Stage I
  • Microwave ablation
  • (no location specified)
May 23, 2023

Breast Cancer, Triple Negative Breast Cancer Trial in United States (Capecitabine, Talazoparib, Atezolizumab)

Recruiting
  • Breast Cancer
  • Triple Negative Breast Cancer
  • Washington, District of Columbia
  • +5 more
Jan 12, 2023

Triple Negative Breast Cancer Trial in Seoul (Atezolizumab, Capecitabine)

Recruiting
  • Triple Negative Breast Cancer
  • Seoul, Korea, Republic of
    Korea University, Guro hospital
Mar 10, 2021

Triple Negative Breast Cancer, Residual Disease Trial (Tetrathiomolybdate, Capecitabine, Pembrolizumab)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Residual Disease
  • (no location specified)
Nov 15, 2023

Breast Cancer Invasive Trial (pyrotinib)

Not yet recruiting
  • Breast Cancer Invasive
  • (no location specified)
Jun 18, 2023

Breast Cancer Trial in Barcelona, Madrid, Valencia (Talimogene laherparepvec, Atezolizumab)

Active, not recruiting
  • Breast Cancer
  • Barcelona, Spain
  • +3 more
Sep 27, 2022

HER2-positive Breast Cancer Trial in Chuo-ku

Recruiting
  • HER2-positive Breast Cancer
    • Chuo-ku, Tokyo, Japan
      National Cancer Center Hospital, Japan
    Jun 22, 2022

    Breast Cancer, Breast Cancer Invasive Trial in Groningen (Fluorescence guided detection of tumor positive margins.)

    Not yet recruiting
    • Breast Cancer
    • Breast Cancer Invasive
    • Fluorescence guided detection of tumor positive margins.
    • Groningen, Netherlands
    • +1 more
    Jul 10, 2023

    Breast Cancer Trial (Pyrotinib, Trastuzumab, Paclitaxel)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Apr 22, 2023

    Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,

    Not yet recruiting
    • Breast Cancer Invasive
    • +3 more
    • Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
    • Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
    • Guangzhou, Guangdong, China
      Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    Nov 17, 2023

    Breast Cancer Stage I Trial (Capecitabine,Pyrotinib)

    Not yet recruiting
    • Breast Cancer Stage I
    • (no location specified)
    May 7, 2023

    Successful Microsurgical Breast Reconstruction in Minimally

    Completed
    • Breast Reconstruction
    • Breast Cancer
      • Taoyuan, Taiwan
        ChangGungMH
      Jul 4, 2023

      Breast, Metastatic, Triple Negative Trial in Gainesville, Jacksonville (Capecitabine, Sarilumab 150mg or 200 mg plus

      Active, not recruiting
      • Breast
      • +4 more
      • Gainesville, Florida
      • +1 more
      Feb 2, 2023

      Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer Trial in Boston (Trastuzumab

      Not yet recruiting
      • Invasive Breast Cancer
      • +4 more
      • Boston, Massachusetts
      • +1 more
      Mar 20, 2023

      Breast Tumors, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer Trial in United States (Z-endoxifen, exemestane,

      Recruiting
      • Breast Neoplasms
      • +3 more
      • Phoenix, Arizona
      • +3 more
      Jan 30, 2023

      Breast Cancer, Triple Negative Breast Cancer, Residual Cancer Trial in United States (Atezolizumab, Sacituzumab govitecan)

      Recruiting
      • Breast Cancer
      • +3 more
      • San Francisco, California
      • +8 more
      May 25, 2022